SCHEMBL16194574

SCHEMBL16194574

CC(C)(C)OC(=O)NC1CCN(Cc2ccc(C#Cc3cccnc3)nc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 1/20 0.47
AKT1 P31749 1/20 0.47
SIGMAR1 Q99720 1/20 0.46
HIF1A Q16665 2/20 0.45
EPAS1 Q99814 2/20 0.45
NPY5R Q15761 4/20 0.44
SMO Q99835 1/20 0.44
KCNA3 P22001 1/20 0.44
CXCR4 P61073 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
DRD4 P21917 1/20 0.43
NSD2 O96028 1/20 0.43
KIT P10721 1/20 0.41
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
PRKAA2 P54646 1/20 0.41
PARP1 P09874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16200832 0.81 SIGMAR1 (0.52) SLC6A5AKT1SIGMAR1NPY5RSMO
SCHEMBL15033052 0.80 SIGMAR1 (0.60) SLC6A5AKT1SIGMAR1NPY5RKCNA3
SCHEMBL6968971 0.79 NPY5R (0.57) SLC6A5AKT1SIGMAR1NPY5RKCNA3
SCHEMBL16200816 0.78 SIGMAR1 (0.52) SLC6A5AKT1SIGMAR1NPY5RKCNA3
SCHEMBL16200819 0.77 KCNH2 (0.48) AKT1SIGMAR1NPY5RKCNA3NSD2
SCHEMBL648348 0.76 SIGMAR1 (0.60) AKT1SIGMAR1KCNA3CHRM2CHRM1
SCHEMBL10135596 0.74 MCHR1 (0.50) SIGMAR1DRD4PARP1PARP2LTA4H
SCHEMBL15615202 0.74 SMO (0.84) SLC6A5AKT1NPY5RSMOCXCR4
SCHEMBL915402 0.74 KMT2A (0.65) SIGMAR1KCNA3DRD4
SCHEMBL15033029 0.73 KCNA3 (0.52) AKT1SIGMAR1KCNA3NSD2PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991981-B1 DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INT (DE) 2017-03-01 EP disclosed
EP-2991981-B1 DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INT (DE) 2017-03-01 EP disclosed
EP-2991981-A1 DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF Boehringer Ingelheim International GmbH (DE) 2016-03-09 EP disclosed
US-9018215-B2 Heteroaromatic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-28 US disclosed
US-9018215-B2 Heteroaromatic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-28 US disclosed
US-9018215-B2 Heteroaromatic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-28 US disclosed
WO-2014177469-A1 DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH,M (DE) 2014-11-06 WO disclosed
WO-2014177469-A1 DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH,M (DE) 2014-11-06 WO disclosed
US-20140323447-A1 HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-30 US disclosed
US-20140323447-A1 HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-30 US disclosed
US-20140323447-A1 HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323447-A1 HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF SCNN1B, SCNN1A, SCNN1G SLC6A5 295/4885AKT1 4421/4885SIGMAR1 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.